1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq

 
• By Michael Cipriano

Labeling for Valeant’s pending plaque psoriasis treatment might warn about the potential for suicide; if that's effective, though, will the company be able to enroll meaningful numbers of patients in its registry that aims for a definitive answer?

Valeant Headquarters

Valeant Pharmaceuticals International Inc. may face a significant challenge in getting a clear answer on whether its plaque psoriasis candidate Siliq (brodalumab) has an increased suicide risk – and efforts to reduce that risk may be part of the problem.

If the product is approved, Valeant is planning to assess Siliq’s potential risk of suicide ideation and behavior with a controlled cohort registry study that aims to include patients taking other treatments for moderate to severe plaque psoriasis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman

Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

‘Pipeline In A Pill’ Or Pipe Dream? US FDA’s April Goal Dates Test Expansion Strategies

 
• By Bridget Silverman

Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.